What do systematic reviews say?

PDEI vs placebo

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 3646 participants
  Low

PDEI vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 550 participants
  Low

PDEI + 5‐ARI vs 5‐ARI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs alpha‐blocker

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs PDEI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found